News

March 31, 2020March 31, 2020

FDA Approves Imfinzi-Chemo Combo to Treat Advanced SCLC

News

The U.S. Food and Drug Administration (FDA) has approved Imfinzi (durvalumab), in combination with standard chemotherapy, as an initial treatment of people with extensive-stage small cell lung cancer (SCLC). This decision ... Read more

March 24, 2020March 31, 2020

Imfinzi Plus Chemo Extends Survival in Advanced Small Cell Lung Cancer, Trial Analysis Shows

News

First-line treatment with Imfinzi (durvalumab) combined with standard chemotherapy significantly prolongs the life of people with extensive-stage small cell lung cancer (SCLC), final results of the CASPIAN Phase 3 ... Read more

March 23, 2020March 23, 2020

Better Responses with IO102-Keytruda Combo Likely in Ongoing NSCLC Trial

News

Adding IO Biotech’s lead candidate, IO102, to first-line treatment with Keytruda (pembrolizumab) is likely to result in better response rates in people with metastatic non-small cell lung cancer (NSCLC), an interim ... Read more

March 20, 2020March 20, 2020

Harbour BioMed Gets FDA Nod to Start US Trials of 2 Immunotherapies

News

The U.S. Food and Drug Administration (FDA) has approved Harbour BioMed’s investigational new drug applications to initiate U.S. clinical trials testing two of its immunotherapy candidates — HBM9167 and HBM4003 — ... Read more

March 18, 2020April 1, 2020

FDA Approves Opdivo-Yervoy Combo for Previously Treated Liver Cancer

News

The U.S. Food and Drug Administration (FDA) approved a combination of Bristol-Myers Squibb‘s immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of hepatocellular carcinoma (HCC) patients ... Read more

March 16, 2020March 16, 2020

Phase 2 Trial of Probody-Opdivo Combo Expanding in Advanced Cancers

News

An ongoing Phase 1/2a trial exploring a type of engineered antibody — the anti-CTLA-4 probody BMS-986249 by CytomX Therapeutics — alone and in combination with Opdivo (nivolumab) in treating advanced solid tumors ... Read more

March 11, 2020March 11, 2020

Imfinzi, Alone or in Combo, Fails at Survival Goals in Advanced Bladder Cancer Trial

News

AstraZeneca‘s immune checkpoint inhibitor Imfinzi (durvalumab), used alone or in combination with investigational tremelimumab in Phase 3 trial in newly diagnosed people with inoperable and metastatic bladder cancer, failed to improve overall survival ... Read more

March 9, 2020March 9, 2020

1st Patient Dosed in UK Trial of Anti-Cancer Virus TG6002

News

Transgene’s TG6002 has been successfully given to a first person in a Phase 1/2a clinical trial testing it in colorectal cancer patients with inoperable liver metastasis, the company announced. ... Read more

March 6, 2020March 6, 2020

Cabiralizumab Plus Opdivo Failed to Halt Progression of Advanced Pancreatic Cancer, Trial Shows

News

Combining Five Prime Therapeutics‘ investigational therapy cabiralizumab with Opdivo (nivolumab) — with and without chemotherapy — failed to halt disease progression in people with advanced pancreatic cancer, compared with ... Read more

March 5, 2020March 5, 2020

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

News

In recognition of Rare Disease Day Feb. 29, BioNews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the ... Read more

Pin It on Pinterest